Immunitas Therapeutics Raises \$58M Series B

Client News August 18, 2021

Gunderson Dettmer represented Immunitas Therapeutics, an immuno-oncology biotech company in its \$58 million Series B financing round. The round will advance their efforts to push a new class of checkpoint inhibitors on to the next stop.

In the announcement of the transaction, CEO Jeffrey Goldberg emphasized the twoyear-old company's quick clinical ambitions. "Immunitas derives from the research of scientists at Harvard's Dana-Farber Cancer Institute, the Massachusetts Institute of Technology and Massachusetts General Hospital. The single-cell sequencing platform gives Immunitas "a lot of powerful data" about every cell in any human tissue sample that it processes," said Goldberg.

The company first emerged in 2019 with funding from Big Pharmas like Bayer and Novartis, through their venture outfits, along with other investment firms.

The Gunderson deal was led by Timothy Ehrlich, George Pothoulakis, Taylor Sarkaria, Chris Warren, and Joel Diamond.

Related People

Timothy H. Ehrlich PARTNER P +1 617 648 9399

Taylor J. Sarkaria

ASSOCIATE P +1 617 648 9317

Christopher K. Warren ASSOCIATE P +1 617 648 9180

Joel T. Diamond ASSOCIATE P +1 617 648 9136

Related Services

Early-Stage Company

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in "Where the legal battle stands around copyright and AI training"

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding